END 7-OH Act
Key claim: The END 7-OH Act (HR8000, 119th Congress) would regulate 7-hydroxymitragynine and has been referred to the House Energy and Commerce and Judiciary committees.
Abstract
(HR8000 · 119th Congress) Latest action (2026-03-19): Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Why this matters
The END 7-OH Act signals congressional interest in statutorily regulating 7-hydroxymitragynine, a potent kratom-derived alkaloid already subject to a concurrent DEA proposed temporary Schedule I placement above a concentration threshold. If enacted, it would shape what kratom-derived products consumers can legally buy and how manufacturers, retailers, and researchers handle 7-OH-containing material. The bill is at an early stage — referred to two House committees — so practical implications for patients and industry depend on whether markup and floor action follow.